Open AccessEvaluation of the influence of the therapy with fosinopril and zofenopril on the regulatory-adaptive status of patients with diastolic chronic heart failure
Author(s) -
Svetla. Nedvetskaya,
Недвецкая Светлана Николаевна,
В. Г. Трегубов,
Трегубов Виталий Германович,
Iosif Z. Shubitidze,
Шубитидзе Иосиф Зурабович,
V. M. Pokrovskiy,
Покровский Владимир Михайлович
Publication year - 2019
Publication title -
cardiosomatika
Language(s) - English
Resource type - Journals
eISSN - 2658-5707
pISSN - 2221-7185
DOI - 10.26442/22217185.2019.4.190657
Subject(s) - fosinopril , medicine , heart failure , nebivolol , ejection fraction , cardiology , diastole , pharmacotherapy , brain natriuretic peptide , ventricle , blood pressure , angiotensin converting enzyme
Aim. Еvaluate the influence of combination therapy with fosinopril or zofenopril on the regulatory-adaptive status (RAS) of patients with diastolic chronic heart failure (CHF). Material and methods. The study includes 80 patients with CHF I-II functional class according to the classification of the New York heart Association with left ventricle ejection fraction ≥50% because of hypertensive disease (HD) of III stage, who were randomized into two groups for treatment with fosinopril (14.7±4.2 mg/day, n=40) or zofenopril (22.5±7.5 mg/day, n=40). As part of combination pharmacotherapy, patients were included nebivolol (7.1±2.0 mg/day and 6.8±1.9 mg/day), in the presence of indications, atorvastatin and acetylsalicylic acid in the intestinal shell were prescribed. Initially and after six months, the following was done: a quantitative evaluation of the RAS (by cardio-respiratory synchronism test), echocardiography, tredmil-test, six-minute walking test, determination of the N-terminal precursor of the natriuretic brain peptide level in blood plasma and subjective evaluation of quality of life. Results. Therapy, using fosinopril, in comparison with zofenopril, more improved RAS (by 66.5%, p